UCB SA (UCB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, UCB SA (UCB) has a cash flow conversion efficiency ratio of 0.032x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€369.00 Million ≈ $431.40 Million USD) by net assets (€11.65 Billion ≈ $13.62 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see UCB company net worth for the company's overall valuation and market capitalisation.
UCB SA - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how UCB SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
UCB SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UCB SA ranked by their cash flow conversion efficiency. Explore UCB SA (UCB) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WEG S.A.
SA:WEGE3
|
0.066x |
|
Adani Power Limited
NSE:ADANIPOWER
|
0.225x |
|
ASM INTL N.V. NY/1 EO-04
F:AVSN
|
0.010x |
|
Agilent Technologies Inc
NYSE:A
|
0.054x |
|
Asia Vital Components Co Ltd
TW:3017
|
0.249x |
|
Haleon plc
NYSE:HLN
|
0.055x |
|
China CSSC Holdings Ltd
SHG:600150
|
0.014x |
|
Adani Ports and Special Economic Zone Limited
NSE:ADANIPORTS
|
0.096x |
Annual Cash Flow Conversion Efficiency for UCB SA (2000–2025)
The table below shows the annual cash flow conversion efficiency of UCB SA from 2000 to 2025. View UCB live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €10.87 Billion ≈ $12.70 Billion |
€2.16 Billion ≈ $2.53 Billion |
0.199x | +60.72% |
| 2024-12-31 | €10.03 Billion ≈ $11.72 Billion |
€1.24 Billion ≈ $1.45 Billion |
0.124x | +46.05% |
| 2023-12-31 | €8.97 Billion ≈ $10.49 Billion |
€761.00 Million ≈ $889.69 Million |
0.085x | -31.32% |
| 2022-12-31 | €9.06 Billion ≈ $10.60 Billion |
€1.12 Billion ≈ $1.31 Billion |
0.123x | -33.34% |
| 2021-12-31 | €8.39 Billion ≈ $9.80 Billion |
€1.55 Billion ≈ $1.82 Billion |
0.185x | +24.58% |
| 2020-12-31 | €7.27 Billion ≈ $8.50 Billion |
€1.08 Billion ≈ $1.26 Billion |
0.149x | +18.13% |
| 2019-12-31 | €7.01 Billion ≈ $8.19 Billion |
€882.00 Million ≈ $1.03 Billion |
0.126x | -27.72% |
| 2018-12-31 | €6.25 Billion ≈ $7.31 Billion |
€1.09 Billion ≈ $1.27 Billion |
0.174x | +7.73% |
| 2017-12-31 | €5.74 Billion ≈ $6.71 Billion |
€927.00 Million ≈ $1.08 Billion |
0.162x | +107.29% |
| 2016-12-31 | €5.48 Billion ≈ $6.40 Billion |
€427.00 Million ≈ $499.21 Million |
0.078x | +75.76% |
| 2015-12-31 | €5.55 Billion ≈ $6.48 Billion |
€246.00 Million ≈ $287.60 Million |
0.044x | -60.71% |
| 2014-12-31 | €4.89 Billion ≈ $5.72 Billion |
€552.00 Million ≈ $645.35 Million |
0.113x | +69.44% |
| 2013-12-31 | €4.32 Billion ≈ $5.05 Billion |
€288.00 Million ≈ $336.70 Million |
0.067x | -13.81% |
| 2012-12-31 | €4.59 Billion ≈ $5.37 Billion |
€355.00 Million ≈ $415.03 Million |
0.077x | +27.66% |
| 2011-12-31 | €4.82 Billion ≈ $5.64 Billion |
€292.00 Million ≈ $341.38 Million |
0.061x | -45.06% |
| 2010-12-31 | €4.59 Billion ≈ $5.37 Billion |
€506.00 Million ≈ $591.57 Million |
0.110x | +64.99% |
| 2009-12-31 | €4.42 Billion ≈ $5.16 Billion |
€295.00 Million ≈ $344.89 Million |
0.067x | -26.70% |
| 2008-12-31 | €4.02 Billion ≈ $4.70 Billion |
€366.00 Million ≈ $427.89 Million |
0.091x | -20.71% |
| 2007-12-31 | €4.26 Billion ≈ $4.99 Billion |
€490.00 Million ≈ $572.86 Million |
0.115x | +71.05% |
| 2006-12-31 | €4.78 Billion ≈ $5.59 Billion |
€321.00 Million ≈ $375.28 Million |
0.067x | -44.19% |
| 2005-12-31 | €2.41 Billion ≈ $2.82 Billion |
€290.00 Million ≈ $339.04 Million |
0.120x | -67.06% |
| 2004-12-31 | €1.96 Billion ≈ $2.30 Billion |
€718.17 Million ≈ $839.61 Million |
0.365x | -3.84% |
| 2003-12-31 | €1.78 Billion ≈ $2.09 Billion |
€677.97 Million ≈ $792.61 Million |
0.380x | -0.34% |
| 2002-12-31 | €1.57 Billion ≈ $1.83 Billion |
€596.97 Million ≈ $697.92 Million |
0.381x | +11.99% |
| 2001-12-31 | €1.39 Billion ≈ $1.63 Billion |
€473.45 Million ≈ $553.51 Million |
0.341x | +18.59% |
| 2000-12-31 | €1.21 Billion ≈ $1.41 Billion |
€346.26 Million ≈ $404.81 Million |
0.287x | -- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more